Literature DB >> 21835972

Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems.

Rong Zhang1,2, Jia-Chang Cai2, Hong-Wei Zhou2, Masao Nasu1, Gong-Xiang Chen2.   

Abstract

Carbapenem resistance in members of the Enterobacteriaceae is increasing. To evaluate the effects of tigecycline and polymyxin B against carbapenem-non-susceptible pathogens, 89 representative clinical carbapenem-non-susceptible Enterobacteriaceae isolates were recovered from seven hospitals from four cities in China during 2006-2009: 30 Serratia marcescens, 35 Klebsiella pneumoniae, seven Enterobacter cloacae, six Enterobacter aerogenes, five Escherichia coli, four Citrobacter freundii and two Klebsiella oxytoca isolates. Twenty-eight S. marcescens isolates were indistinguishable. The 35 K. pneumoniae isolates belonged to 12 clonal strains. Among the 89 Enterobacteriaceae isolates, 82 produced KPC-2, seven produced IMP (three produced KPC-2 simultaneously), three did not produce any carbapenemases and nine were deficient in porins. Polymyxin B was much more active than tigecycline against carbapenem-non-susceptible Enterobacteriaceae. The MIC(50) and MIC(90) of imipenem, meropenem, ertapenem, polymyxin B and tigecycline were 8 and 32 µg ml(-1), 8 and 32 µg ml(-1), 16 and 128 µg ml(-1), 0.5 and 16 µg ml(-1), and 4 and 16 µg ml(-1), respectively. Rates of susceptibility to imipenem, meropenem, ertapenem and polymyxin B were 30.0%, 27.5%, 2.5% and 89.2% by CLSI criteria. The rate of susceptibility to tigecycline was 40% and 17.5% by Food and Drug Administration (MIC ≤2 µg ml(-1)) and European Committee on Antimicrobial Susceptibility Testing (MIC ≤1 µg ml(-1)) criteria, respectively. KPC-2- or IMP-producing E. coli transconjugants exhibited reduced susceptibility to carbapenems but were susceptible to polymyxin B and tigecycline with an MIC range of 0.5-2 µg ml(-1), 0.25-2 µg ml(-1), 0.5-4 µg ml(-1), 0.5 µg ml(-1) and 0.5-1 µg ml(-1). In conclusion, carbapenem resistance in Enterobacteriaceae is mainly due to production of KPC-2, and polymyxin B is active for the carbapenem-resistant Enterobacteriaceae.
© 2011 SGM

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835972     DOI: 10.1099/jmm.0.025668-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

1.  Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Qi-Min Teo; Suranthran Sasikala; Eric Chun Yong Chan; Yan Jun Hong; Winnie Lee; Thean Yen Tan; Thuan Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 2.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

4.  Infections Caused by Antimicrobial Drug-Resistant Saprophytic Gram-Negative Bacteria in the Environment.

Authors:  Eva Raphael; Lee W Riley
Journal:  Front Med (Lausanne)       Date:  2017-10-30

5.  Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms.

Authors:  Qiong Lu; Guo-Hua Li; Qiang Qu; Hai-Hong Zhu; Yue Luo; Han Yan; Hai-Yan Yuan; Jian Qu
Journal:  Infect Drug Resist       Date:  2021-05-28       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.